Literature DB >> 21978001

NOD-like receptors and RIG-I-like receptors in human eosinophils: activation by NOD1 and NOD2 agonists.

Anne Månsson Kvarnhammar1, Terese Petterson, Lars-Olaf Cardell.   

Abstract

NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs) are newly discovered pattern-recognition receptors. They detect substructures of bacterial peptidoglycan and viral RNA, respectively, thereby initiating an immune response. However, their role in eosinophil activation remains to be explored. The aim of this study was to characterize the expression of a range of NLRs and RLRs in purified human eosinophils and assess their functional importance. Expression of NOD1, NOD2, NLRP3, RIG-I and MDA-5 was investigated using real-time reverse transcription PCR, flow cytometry and immunohistochemistry. The effects of the corresponding agonists iE-DAP (NOD1), MDP (NOD2), alum (NLRP3) and poly(I:C)/LyoVec (RIG-I/MDA-5) were studied in terms of cytokine secretion, degranulation, survival, expression of adhesion molecules and activation markers, and chemotactic migration. Eosinophils expressed NOD1 and NOD2 mRNA and protein. Low levels of RIG-I and MDA-5 were found, whereas expression of NLRP3 was completely absent. In accordance, stimulation with iE-DAP and MDP was found to induce secretion of interleukin-8, up-regulate expression of CD11b, conversely down-regulate CD62 ligand, increase expression of CD69 and induce migration. The MDP also promoted release of eosinophil-derived neurotoxin, whereas iE-DAP failed to do so. No effects were seen upon stimulation with alum or poly(I:C)/LyoVec. Moreover, the NOD1-induced and NOD2-induced activation was mediated via the nuclear factor-κB signalling pathway and augmented by interleukin-5 and granulocyte-macrophage colony-stimulating factor, but not interferon-γ. Taken together, the NLR system represents a novel pathway for eosinophil activation. The responses are enhanced in the presence of cytokines that regulate T helper type 2 immunity, suggesting that the NLRs constitute a link between respiratory infections and exacerbations of allergic disease.
© 2011 The Authors. Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21978001      PMCID: PMC3209571          DOI: 10.1111/j.1365-2567.2011.03492.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  46 in total

1.  Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB.

Authors:  Y Ogura; N Inohara; A Benito; F F Chen; S Yamaoka; G Nunez
Journal:  J Biol Chem       Date:  2000-11-21       Impact factor: 5.157

2.  NOD1 variation, immunoglobulin E and asthma.

Authors:  Pirro Hysi; Michael Kabesch; Miriam F Moffatt; Michaela Schedel; David Carr; Youming Zhang; Brenda Boardman; Erika von Mutius; Stephan K Weiland; Wolfgang Leupold; Christian Fritzsch; Norman Klopp; A William Musk; Alan James; Gabriel Nunez; Naohiro Inohara; William O C Cookson
Journal:  Hum Mol Genet       Date:  2005-02-17       Impact factor: 6.150

Review 3.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

4.  Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.

Authors:  Hiroyuki Tada; Setsuya Aiba; Ken-Ichiro Shibata; Toshiaki Ohteki; Haruhiko Takada
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Association of NOD1 polymorphisms with atopic eczema and related phenotypes.

Authors:  Stephan Weidinger; Norman Klopp; Lars Rummler; Stefan Wagenpfeil; Natalija Novak; Hans-Joerg Baurecht; Werner Groer; Ulf Darsow; Joachim Heinrich; Anke Gauger; Torsten Schafer; Thilo Jakob; Heidrun Behrendt; Hans-Erich Wichmann; Johannes Ring; Thomas Illig
Journal:  J Allergy Clin Immunol       Date:  2005-07       Impact factor: 10.793

Review 6.  Eosinophil trafficking to sites of allergic inflammation.

Authors:  D Broide; P Sriramarao
Journal:  Immunol Rev       Date:  2001-02       Impact factor: 12.988

7.  Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture.

Authors:  S Yang; R Tamai; S Akashi; O Takeuchi; S Akira; S Sugawara; H Takada
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 8.  Respiratory infections and asthma.

Authors:  E Micillo; A Bianco; D D'Auria; G Mazzarella; G F Abbate
Journal:  Allergy       Date:  2000       Impact factor: 13.146

9.  Endothelial cells modulate eosinophil surface markers and mediator release.

Authors:  M J Dallaire; C Ferland; N Pagé; S Lavigne; F Davoine; M Laviolette
Journal:  Eur Respir J       Date:  2003-06       Impact factor: 16.671

10.  Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand.

Authors:  Hiroyuki Nagase; Shu Okugawa; Yasuo Ota; Masao Yamaguchi; Hideyuki Tomizawa; Kouji Matsushima; Ken Ohta; Kazuhiko Yamamoto; Koichi Hirai
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

View more
  16 in total

Review 1.  Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets.

Authors:  Vikas Mishra; Jaspreet Banga; Patricia Silveyra
Journal:  Pharmacol Ther       Date:  2017-08-23       Impact factor: 12.310

Review 2.  Pattern-recognition receptors in human eosinophils.

Authors:  Anne Månsson Kvarnhammar; Lars Olaf Cardell
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

Review 3.  Eosinophils: Nemeses of Pulmonary Pathogens?

Authors:  Kim S LeMessurier; Amali E Samarasinghe
Journal:  Curr Allergy Asthma Rep       Date:  2019-06-19       Impact factor: 4.806

4.  Aberrant expression of regulatory cytokine IL-35 and pattern recognition receptor NOD2 in patients with allergic asthma.

Authors:  Chun Kwok Wong; Ting Fan Leung; Ida Miu Ting Chu; Jie Dong; Yvonne Yi On Lam; Christopher Wai Kei Lam
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

5.  Impact of eosinophil-peroxidase (EPX) deficiency on eosinophil structure and function in mouse airways.

Authors:  Caroline M Percopo; Julia O Krumholz; Elizabeth R Fischer; Laura S Kraemer; Michelle Ma; Karen Laky; Helene F Rosenberg
Journal:  J Leukoc Biol       Date:  2018-10-04       Impact factor: 4.962

6.  NOD-like receptors mediated activation of eosinophils interacting with bronchial epithelial cells: a link between innate immunity and allergic asthma.

Authors:  Chun Kwok Wong; Shuiqing Hu; Karen Ming-Lam Leung; Jie Dong; Lan He; Yi Jun Chu; Ida Miu-Ting Chu; Huai-Na Qiu; Kelly Yan-Ping Liu; Christopher Wai-Kei Lam
Journal:  Cell Mol Immunol       Date:  2013-03-25       Impact factor: 11.530

7.  Muramyl dipeptide mediated activation of human bronchial epithelial cells interacting with basophils: a novel mechanism of airway inflammation.

Authors:  H N Qiu; C K Wong; I M T Chu; S Hu; C W K Lam
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

8.  NOD1 activation induces cardiac dysfunction and modulates cardiac fibrosis and cardiomyocyte apoptosis.

Authors:  María Fernández-Velasco; Patricia Prieto; Verónica Terrón; Gemma Benito; Juana M Flores; Carmen Delgado; Carlos Zaragoza; Begoña Lavin; Mónica Gómez-Parrizas; Eduardo López-Collazo; Paloma Martín-Sanz; Lisardo Boscá
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

9.  Gene-specific sex effects on eosinophil infiltration in leishmaniasis.

Authors:  Martina Slapničková; Valeriya Volkova; Marie Čepičková; Tatyana Kobets; Matyáš Šíma; Milena Svobodová; Peter Demant; Marie Lipoldová
Journal:  Biol Sex Differ       Date:  2016-11-22       Impact factor: 5.027

10.  Innate immune receptors in human airway smooth muscle cells: activation by TLR1/2, TLR3, TLR4, TLR7 and NOD1 agonists.

Authors:  Anne Månsson Kvarnhammar; Lotta Tengroth; Mikael Adner; Lars-Olaf Cardell
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.